Handelsavisen
prelaunch
Companies ›Healthcare ›300239.SZ
30
300239.SZ — Shenzhen Stock Exchange Pharmaceuticals

Baotou Dongbao Bio-Tech Co Ltd

¥5,09
Open in Charts → Attach watcher ⌖
— —
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,45 %
Op margin
8,0 %
ROE
3,1 %
Net margin
7,3 %
Debt / equity
0,32
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Baotou Dongbao Bio-Tech Co Ltd is a pharmaceutical company engaged in the research, development, production, and sale of biopharmaceutical products, primarily in the Chinese market.

Business. Baotou Dongbao Bio-Tech Co Ltd (300239.SZ) is a pharmaceutical company headquartered in China that operates within the healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
3,1 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 300239.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 300239.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Baotou Dongbao Bio-Tech Co Ltd (300239.SZ) is a pharmaceutical company headquartered in China that operates within the healthcare sector. The firm is primarily engaged in the development and sale of pharmaceutical products. It is listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    ### Capital Structure and Liquidity Baotou Dongbao Bio-Tech maintains a debt-to-equity ratio of 0.32, indicating a relatively conservative capital structure. The company's liquidity position is assessed as medium, with a current ratio of 4.87, suggesting strong short-term liquidity. However, the company has a negative net cash position after subtracting total debt, which introduces some liquidity risk.

    ### Profitability and Returns The company's return on equity (ROE) is 3.15%, and its return on assets (ROA) is 2.13%, both of which are below the industry median for pharmaceutical firms. This suggests that the company is underperforming in terms of capital efficiency and asset utilization.

    ### Segments and Geographic Exposure The company's revenue is concentrated in its domestic operations, with no disclosed international revenue segments. This geographic concentration increases exposure to local regulatory and economic conditions.

    ### Growth Trajectory The company's revenue for the latest period is 745.31 million CNY. While the company has a positive operating cash flow of 105.92 million CNY, its capital expenditures are negative at -79.27 million CNY, indicating a reduction in investment in physical assets. The outlook for the current fiscal year is neutral, with no significant revenue growth expected in the near term.

    ### Risk Factors The company faces moderate liquidity risk due to its negative net cash position after debt. The dilution risk is assessed as low, with no significant dilution expected in the near term. The company has not disclosed any recent share issuance or dilutive events.

    ### Recent Events The company has not disclosed any recent material events, such as regulatory actions, major product launches, or significant management changes, in the latest filings.

    Key takeaways
    • The company has a conservative capital structure with a debt-to-equity ratio of 0.32.
    • ROE and ROA are below industry medians, indicating suboptimal returns on equity and assets.
    • Revenue is concentrated in domestic operations, increasing exposure to local market conditions.
    • The company is not investing in new physical assets, as indicated by negative capital expenditures.
    • Liquidity risk is moderate, and dilution risk is low.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥5,09
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    ¥1.72B
    Net cashⓘ
    -¥545.7M
    Current ratioⓘ
    4.9
    Debt / equityⓘ
    0.3
    ROAⓘ
    2.1%
    ROEⓘ
    3.1%
    Cash conversionⓘ
    195.0%
    CapEx / revenueⓘ
    -10.6%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin8,0 %Above median
    Net Margin7,3 %Above median
    ROE3,1 %Above median
    Capex / Rev-10,6 %Below median
    D/E0,32Below median
    Cash Conv1,95Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Baotou Dongbao Bio-Tech Co Ltd Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    300239.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage